Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma

Anil Potti, Apar Kishor P Ganti, Michael Koch, Ralph Levitt, Syed A. Mehdi

Research output: Contribution to journalLetter

11 Citations (Scopus)

Abstract

Multiple myeloma (MM) is the most common plasma cell dyscrasia. Conventional therapy results in a median survival of 3-5 years. Patients with B-cell disorders and coexistent HER-2/neu overexpression in solid tumors have a poorer prognosis than those without an underlying B-cell disorder. This, and the recent success of the tyrosine kinase inhibitor, imatinib mesylate in chronic myelogenous leukemia, led us to evaluate the incidence and role of c-kit (CD117) and HER-2/neu overexpression in MM. We conducted a retrospective study to determine the incidence of HER-2/neu and c-kit overexpression in MM. HER-2/neu overexpression was evaluated using the DAKO Hercep test and c-kit overexpression was assessed using conventional immunohistochemistry (IHC); 69 patients with a diagnosis of MM were identified, of whom, 31 patients (19 males and 12 females) had an adequate pathological specimen available for IHC testing; 4 out of 31 patients (12.9%) showed HER-2/neu overexpression, while 5/31 (16.13%) showed CD117 expression. Two patients (6.45%) showed both HER-2/neu and c-kit overexpression. Although both HER-2/neu and c-kit are not expressed very frequently in patients with MM, there appears to be a subgroup of patients in whom, either one or both these oncogenes is overexpressed. Given our small sample size, it is difficult to comment on the effect of CD117 and/or HER-2/neu overexpression on survival. Future larger studies are needed to define the association in MM and to determine if the presence of one (CD117 or HER-2/neu) has an effect on overexpression of the other oncoprotein. Furthermore, it would be beneficial to identify the molecular nature of the interplay between HER-2/neu and c-kit, if any. Target-directed signal transduction inhibition therapy using tyrosine kinase inhibitors, may be a distinct possibility in a select group of patients with MM.

Original languageEnglish (US)
Pages (from-to)2427-2430
Number of pages4
JournalLeukemia and Lymphoma
Volume43
Issue number12
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Multiple Myeloma
Protein-Tyrosine Kinases
B-Lymphocytes
Immunohistochemistry
Paraproteinemias
Survival
Oncogene Proteins
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenes
Sample Size
Signal Transduction
Retrospective Studies
Therapeutics
Neoplasms

Keywords

  • HER-2/neu overexpression
  • Multiple myeloma
  • Outcome
  • c-Kit

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. / Potti, Anil; Ganti, Apar Kishor P; Koch, Michael; Levitt, Ralph; Mehdi, Syed A.

In: Leukemia and Lymphoma, Vol. 43, No. 12, 01.12.2002, p. 2427-2430.

Research output: Contribution to journalLetter

Potti, Anil ; Ganti, Apar Kishor P ; Koch, Michael ; Levitt, Ralph ; Mehdi, Syed A. / Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma. In: Leukemia and Lymphoma. 2002 ; Vol. 43, No. 12. pp. 2427-2430.
@article{0f570d3e4b2c4a939a6a113d34385ccf,
title = "Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma",
abstract = "Multiple myeloma (MM) is the most common plasma cell dyscrasia. Conventional therapy results in a median survival of 3-5 years. Patients with B-cell disorders and coexistent HER-2/neu overexpression in solid tumors have a poorer prognosis than those without an underlying B-cell disorder. This, and the recent success of the tyrosine kinase inhibitor, imatinib mesylate in chronic myelogenous leukemia, led us to evaluate the incidence and role of c-kit (CD117) and HER-2/neu overexpression in MM. We conducted a retrospective study to determine the incidence of HER-2/neu and c-kit overexpression in MM. HER-2/neu overexpression was evaluated using the DAKO Hercep test and c-kit overexpression was assessed using conventional immunohistochemistry (IHC); 69 patients with a diagnosis of MM were identified, of whom, 31 patients (19 males and 12 females) had an adequate pathological specimen available for IHC testing; 4 out of 31 patients (12.9{\%}) showed HER-2/neu overexpression, while 5/31 (16.13{\%}) showed CD117 expression. Two patients (6.45{\%}) showed both HER-2/neu and c-kit overexpression. Although both HER-2/neu and c-kit are not expressed very frequently in patients with MM, there appears to be a subgroup of patients in whom, either one or both these oncogenes is overexpressed. Given our small sample size, it is difficult to comment on the effect of CD117 and/or HER-2/neu overexpression on survival. Future larger studies are needed to define the association in MM and to determine if the presence of one (CD117 or HER-2/neu) has an effect on overexpression of the other oncoprotein. Furthermore, it would be beneficial to identify the molecular nature of the interplay between HER-2/neu and c-kit, if any. Target-directed signal transduction inhibition therapy using tyrosine kinase inhibitors, may be a distinct possibility in a select group of patients with MM.",
keywords = "HER-2/neu overexpression, Multiple myeloma, Outcome, c-Kit",
author = "Anil Potti and Ganti, {Apar Kishor P} and Michael Koch and Ralph Levitt and Mehdi, {Syed A.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1080/1042819021000040198",
language = "English (US)",
volume = "43",
pages = "2427--2430",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma

AU - Potti, Anil

AU - Ganti, Apar Kishor P

AU - Koch, Michael

AU - Levitt, Ralph

AU - Mehdi, Syed A.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Multiple myeloma (MM) is the most common plasma cell dyscrasia. Conventional therapy results in a median survival of 3-5 years. Patients with B-cell disorders and coexistent HER-2/neu overexpression in solid tumors have a poorer prognosis than those without an underlying B-cell disorder. This, and the recent success of the tyrosine kinase inhibitor, imatinib mesylate in chronic myelogenous leukemia, led us to evaluate the incidence and role of c-kit (CD117) and HER-2/neu overexpression in MM. We conducted a retrospective study to determine the incidence of HER-2/neu and c-kit overexpression in MM. HER-2/neu overexpression was evaluated using the DAKO Hercep test and c-kit overexpression was assessed using conventional immunohistochemistry (IHC); 69 patients with a diagnosis of MM were identified, of whom, 31 patients (19 males and 12 females) had an adequate pathological specimen available for IHC testing; 4 out of 31 patients (12.9%) showed HER-2/neu overexpression, while 5/31 (16.13%) showed CD117 expression. Two patients (6.45%) showed both HER-2/neu and c-kit overexpression. Although both HER-2/neu and c-kit are not expressed very frequently in patients with MM, there appears to be a subgroup of patients in whom, either one or both these oncogenes is overexpressed. Given our small sample size, it is difficult to comment on the effect of CD117 and/or HER-2/neu overexpression on survival. Future larger studies are needed to define the association in MM and to determine if the presence of one (CD117 or HER-2/neu) has an effect on overexpression of the other oncoprotein. Furthermore, it would be beneficial to identify the molecular nature of the interplay between HER-2/neu and c-kit, if any. Target-directed signal transduction inhibition therapy using tyrosine kinase inhibitors, may be a distinct possibility in a select group of patients with MM.

AB - Multiple myeloma (MM) is the most common plasma cell dyscrasia. Conventional therapy results in a median survival of 3-5 years. Patients with B-cell disorders and coexistent HER-2/neu overexpression in solid tumors have a poorer prognosis than those without an underlying B-cell disorder. This, and the recent success of the tyrosine kinase inhibitor, imatinib mesylate in chronic myelogenous leukemia, led us to evaluate the incidence and role of c-kit (CD117) and HER-2/neu overexpression in MM. We conducted a retrospective study to determine the incidence of HER-2/neu and c-kit overexpression in MM. HER-2/neu overexpression was evaluated using the DAKO Hercep test and c-kit overexpression was assessed using conventional immunohistochemistry (IHC); 69 patients with a diagnosis of MM were identified, of whom, 31 patients (19 males and 12 females) had an adequate pathological specimen available for IHC testing; 4 out of 31 patients (12.9%) showed HER-2/neu overexpression, while 5/31 (16.13%) showed CD117 expression. Two patients (6.45%) showed both HER-2/neu and c-kit overexpression. Although both HER-2/neu and c-kit are not expressed very frequently in patients with MM, there appears to be a subgroup of patients in whom, either one or both these oncogenes is overexpressed. Given our small sample size, it is difficult to comment on the effect of CD117 and/or HER-2/neu overexpression on survival. Future larger studies are needed to define the association in MM and to determine if the presence of one (CD117 or HER-2/neu) has an effect on overexpression of the other oncoprotein. Furthermore, it would be beneficial to identify the molecular nature of the interplay between HER-2/neu and c-kit, if any. Target-directed signal transduction inhibition therapy using tyrosine kinase inhibitors, may be a distinct possibility in a select group of patients with MM.

KW - HER-2/neu overexpression

KW - Multiple myeloma

KW - Outcome

KW - c-Kit

UR - http://www.scopus.com/inward/record.url?scp=0036891253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036891253&partnerID=8YFLogxK

U2 - 10.1080/1042819021000040198

DO - 10.1080/1042819021000040198

M3 - Letter

VL - 43

SP - 2427

EP - 2430

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -